(+/-)-phenserine | 785027-97-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (+/-)-phenserine
• 英文别名: phenyl-carbamic acid-(1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydro-pyrrolo[2,3-b]indol-5-yl ester)；Phenyl-carbamidsaeure-(1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydro-pyrrolo[2,3-b]indol-5-ylester)；Tributylaminen-oxide；(3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl) N-phenylcarbamate
• CAS: 785027-97-6
• 化学式: C₂₀H₂₃N₃O₂
• 分子量: 337.422
• InChiKey: PBHFNBQPZCRWQP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  44.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (+/-)-phenserine 、 异氰酸苯酯 生成 alkaline earth salt of/the/ methylsulfuric acid
  参考文献：
  名称：

  Polonovski, Bulletin de la Societe Chimique de France, 1916, vol. <4> 19, p. 47,50

  摘要：

  DOI：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 溶剂黄146 、 锌 作用下， 生成 (+/-)-phenserine
  参考文献：
  名称：

  Polonovski, Bulletin de la Societe Chimique de France, 1916, vol. <4> 19, p. 47,50

  摘要：

  DOI：

文献信息

• NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION
  申请人：Barlow Carrolee

  公开号：US20110319386A1

  公开（公告）日：2011-12-29

  The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.
• [EN] METHOD AND COMPOSITION FOR TREATING ALZHEIMER-TYPE DEMENTIA<br/>[FR] MÉTHODE ET COMPOSITION POUR TRAITER LA DÉMENCE DU TYPE ALZHEIMER
  申请人：CHASE PHARMACEUTICALS CORP

  公开号：WO2011034568A1

  公开（公告）日：2011-03-24

  There is described a method for increasing the maximal tolerated dose and thus the efficacy of an acetyl choline esterase inhibitor (AChEI) in a patient suffering from an Alzheimer type dementia by decreasing concomitant adverse effects by administration of said AChEI in combination with a non-anticholinergic antiemetic agent, whereby an enhanced acetyl choline esterase inhibition in the CNS of said patient is achieved and alleviation of the symptoms of Alzheimer type dementia in said patient is thereby improved to a greater extent. The use of a non-anticholinergic antiemetic agent for the preparation of a pharmaceutical composition for the treatment of Alzheimer type dementia in combination with an acetyl choline esterase inhibitor (AChEI) and pharmaceutical compositions comprising (a) a 5HT3 receptor antagonist, a dopamine antagonist, a H1-receptor antagonist, a cannabinoid agonist, aprepitant or casopitant as an antiemetic agent and (b) an acetylcholine esterase inhibitor are also described.
• [EN] NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION<br/>[FR] NEUROGÉNÈSE PAR UNE MODULATION D'UN RÉCEPTEUR MUSCARINIQUE
  申请人：BRAINCELLS INC

  公开号：WO2012170599A1

  公开（公告）日：2012-12-13

  The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.
• Polonovski, Bulletin de la Societe Chimique de France, 1916, vol. <4> 19, p. 47,50
  作者：Polonovski

  DOI：——

  日期：——